Aurinia Pharmaceuticals Inc. (AUPH): what the price assumes

In the published model solve dated 2026-Q2, anchored at $16.08, Aurinia Pharmaceuticals Inc. (AUPH) is priced for +10.3% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-07-25.

Generated: 2026-09-07 · Exported: 2026-09-09 · Source: https://boothcheck.com/report/AUPH

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 5: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 10.3% cost of capital with 4% terminal growth over a 5-year stage.

How unusual the bet is: n/a

Valuation X-Ray

The price is supported by asset-based and earnings-power and relative-multiple and growth-DCF value. A value/asset-supported name, not a pure growth bet.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that justify the price: Asset, Earnings, Relative, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.9%); the inversion above states its own rate.

Per-Model Detail (n=17)

Economic-Unit Decomposition (Sum Of The Parts)

Only one reportable economic unit is present in the current topology source. Consolidated operating lenses remain available, but there is no multi-unit decomposition.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Bullet Takeaways

• Essentially all revenue comes from one medicine, and the 10-K says so directly: the business is "substantially dependent on our ability to successfully commercialize LUPKYNIS, our sole approved product".
• That single product converts unusually well, turning 41.7% of sales into operating profit on a trailing basis, which puts it alongside the most profitable specialty pharma names in its cohort rather than among the loss-makers.
• Reported bottom-line profit for 2025 is flattered by an accounting event that will not repeat: the 10-K discloses that "The Company's net valuation allowance decreased from $154.4 million to zero as of December 31, 2024 and 2025", so operating profit is the honest measure to track from here.

Bull Case

The advantage here is narrow, legal, and unusually well monetised. LUPKYNIS is the approved therapy for lupus nephritis, a kidney complication of lupus that used to be treated, in the 10-K's own description, with an "off-label combination of MMF and corticosteroids alone or in combination with first generation CNIs such as tacrolimus". Being the labelled option in a disease previously managed off-label is a specific kind of position: prescribers do not have to be persuaded that the disease matters, only that a tested product beats improvisation.

The economics show what that position is worth. Aurinia converts 41.7% of sales into operating profit on a trailing basis. Inside its own cohort, only CPRX at a 44.8% operating margin and KRYS at 42.8% do better; INVA runs 38.1%, HALO 33.9%, HRMY 21.1%, ANIP 13.4%, KNSA 12.4%, and SUPN is negative at minus 7.8%. A single-product company usually pays for that concentration with a fragile cost structure. This one has the opposite profile, because one medicine sold to one specialist audience needs one small commercial organization.

Supply is locked down in a way that is easy to overlook. The company describes securing dedicated manufacturing capacity for voclosporin, paying "a quarterly fixed facility fee of 3.6 million Swiss Francs for the exclusive right to use the Monoplant through March 31, 2030", which expands capacity while providing supply security for future commercial demand. Cost of revenue was $32.7 million in 2025 against $28.2 million in 2024, so the input side is behaving predictably while sales grow. For a specialty medicine, manufacturing interruption is one of the few risks that can take the whole business offline, and the company has paid a fixed fee to remove it through the end of the decade.

Growth has kept coming without a change of story. LUPKYNIS net product sales reached $271.3 million in 2025, up 25%, inside total revenue of $283.1 million, and first-quarter 2026 product sales of $73.6 million were up 23% from $60.0 million a year earlier. Adoption is the driver rather than price, which is the durable version of pharmaceutical growth.

The second act is real rather than notional. Aritinercept, described in the filing as "a dual inhibitor of B cell-activating factor ("BAFF") and a proliferation-inducing ligand ("APRIL") for the potential treatment of autoimmune diseases", has produced human data the company summarises as "robust and long-lasting reductions in immunoglobulins (antibodies) in humans". A dual BAFF/APRIL inhibitor addresses a mechanism common to many autoimmune diseases, so the option is broad rather than a second bet on the same disease. It is funded out of operating cash rather than out of shareholders, which is the part that separates this from most biotech optionality.

Capital allocation matches. The board approved a repurchase plan of up to $150 million and then added another $150 million on July 31, 2025, and share count has actually shrunk about 0.7% a year over the four years to March 2026. Leverage is immaterial, with net debt under a fifth of a year's operating profit and interest covered roughly 29 times.

Bear Case

The variable with the most leverage over this thesis is not competition. It is the price of the drug, and Aurinia does not set that alone. The 10-K describes participation in "the Medicaid Drug Rebate Program, administered by CMS, and other federal and state government pricing programs in the U.S.", noting that these "generally require us to pay rebates or otherwise provide discounts to government payors". Layered on top, co-payment assistance and payor rebates are both recorded as reductions of revenue. What reaches the income statement is therefore a net number that a policy change can compress without any change in prescription volume. A specialty medicine with a 41.7% operating margin has a lot of room between gross and net for a payer to reach into.

Exclusivity is the second external clock. The filing walks through the generic-challenge mechanic in detail: a challenger files a certification of invalidity or non-infringement, and patent litigation "will trigger an automatic stay in the approval of any generic competition until the earlier of: (i) 30 months from the certification; or (ii) a court ruling of patent invalidity or non-infringement for the relevant patents". That stay is a delay, not a defence. Concentration makes the consequence unusually blunt, because the 10-K states the company is "substantially dependent on our ability to successfully commercialize LUPKYNIS, our sole approved product".

Now the awkward accounting point. Reported profitability for 2025 looks far better than the business earned, because the company released a large deferred tax asset reserve: "The Company's net valuation allowance decreased from $154.4 million to zero as of December 31, 2024 and 2025, respectively, due to the change in realizability of deferred tax assets and corresponding valuation allowance release." That is a non-cash accounting event and it will not recur. Anyone anchoring on the trailing bottom line, or on a per-share earnings multiple built from it, is comparing today's price to a number the business will not produce again.

The price itself is not the problem, and it is worth being precise about that. At roughly 16 times operating profit, the assumption embedded is operating profit compounding around 15.5% a year over a five-year run. That is unremarkable against what Aurinia has recently delivered. But the base rate is a coin flip: only about 48% of comparable fast growers held such a pace that long. And the growth has to come from the same disease, the same label, and the same prescriber base, because aritinercept is years from contributing revenue. Guidance for 2026 already implies a step down in pace, at total revenue of $315 million to $325 million against $283.1 million in 2025.

The competitive picture is also less quiet than the label suggests. The filing acknowledges that physicians "continue to treat LN with an off-label combination of MMF and corticosteroids", which means the true competitor is a cheap generic regimen that never needed approval. And on the pipeline, the company notes that "aritinercept is subject to competition from both FDA-approved and investigational products" in a mechanism class that several larger companies are pursuing. The bear case here is not that Aurinia is expensive. It is that a one-product company facing payer compression, a finite exclusivity window and a crowded next-generation field deserves to be discounted, and the discount is the market doing arithmetic rather than making a mistake.

Valuation

Something unusual shows up when the methods are laid side by side: not one group of them lands below today's price. Peer multiples, book-value-plus-profitability, capitalized earning power and the forward cash-flow approaches all reach or exceed it, with the earnings-power group sitting essentially level and the peer-multiple group furthest above. That pattern is rare, and it changes what the section has to explain. The question stops being whether the price outruns the evidence and becomes why a business generating this much profit trades where it does.

The assumption inside the price is modest. At roughly 16 times company-wide operating profit, the arithmetic needs operating profit to compound around 15.5% a year over a five-year run and then settle to a slower terminal pace. Aurinia has recently delivered more than that. The countable caution is the base rate rather than the rate itself: only about 48% of comparable fast growers held a pace like that for as long. Nothing here requires a re-rating or a new product to justify the quote.

The concrete "what has to be true" is a margin statement, and the company is already there. Aurinia turns 41.7% of sales into operating profit on a trailing basis. Set against the specialty pharma names it sits with, that is near the top: CPRX earns a 44.8% operating margin, KRYS 42.8%, INVA 38.1%, HALO 33.9%, HRMY 21.1% and KNSA 12.4%. The price is not asking for margin expansion. It is asking for the current margin to survive contact with payers and, eventually, with a generic.

One number in the reported accounts needs setting aside before any of this reads correctly. The 10-K discloses that "The Company's net valuation allowance decreased from $154.4 million to zero as of December 31, 2024 and 2025", a deferred tax accounting release rather than a business result. Operating profit, not the bottom line, is the measure the price should be read against, and that is the measure used above.

Solvency does not constrain anything. Net debt sits under a fifth of a year's operating profit with interest covered roughly 29 times, there is no cash burn, and free cash flow of about 166.9 million dollars comfortably exceeds operating profit. Share count has fallen roughly 0.7% a year over the four years to March 2026 under a repurchase plan the board authorized for 150 million dollars and then expanded by a further 150 million on July 31, 2025. The result is a company whose downside is governed by the durability of one revenue stream rather than by anything on its balance sheet, which is precisely why the standard methods and the market disagree about what it is worth.

Catalysts

The 2026 guidance is the near-term frame. Aurinia has set total revenue of $315 million to $325 million for the year, up 11% to 15%, with net product sales of $305 million to $315 million, and reiterated that outlook alongside first-quarter results. Reaffirmation after a quarter is a more informative event than the original issue, because it means the first three months of actual prescriptions did not argue with the plan.

Underneath it, the prescription trend has stayed intact. First-quarter 2026 LUPKYNIS net product sales were $73.6 million against $60.0 million in the same quarter of 2025, following full-year 2025 net product sales of $271.3 million, up 25%, inside total 2025 revenue of $283.1 million. The gap between that recent pace and the pace implied by full-year guidance is the thing to watch across the next two prints, since guidance implies deceleration and the quarters so far do not.

Aritinercept is the item that changes the shape of the company rather than the year. The company has started a clinical study of the dual BAFF/APRIL inhibitor in one autoimmune disease and has said it plans to begin a study in an additional indication during the first half of 2026. The 10-K reports that single doses produced "robust and long-lasting reductions in immunoglobulins (antibodies) in humans" and that anti-drug antibodies detected at higher dose levels were "not associated with any changes in safety, pharmacokinetic ("PK") or PD parameters". Read-outs from those studies, not quarterly sales, are what would move Aurinia from a one-product company to something else.

Peer Cohorts (Per Segment, With Filing Citations)

Aurinia Pharmaceuticals (consolidated) (reported)

• INVA (INNOVIVA, INC.)
• FY2025 10-K: …product candidate. We received an upfront payment of $ 1.6 million, of which we recognized $ 0.1 million as grant revenue included in "License and other revenue" in our consolidated financial statements for the year ended December 31, 2025. The remaining balance of the upfront payment is recorded as deferred revenue…
• FY2025 10-K: …intra-abdominal infections in adults; • ZEVTERA ® (ceftobiprole), an advanced-generation cephalosporin antibiotic for the treatment of staphylococcus aureus bacteremia , including those with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia,…
• ANIP (ANI PHARMACEUTICALS, INC)
• FY2025 10-K: …LLC and ANI Pharmaceuticals, Inc. (2) Incorporated by reference to Exhibit 10.2 to ANI's Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2016 (File No. 001-31812) 10.15* Ame nded and Re stated ANI Pharmaceuticals, Inc. 2016 Employee Stock Purchase Plan Incorporated by reference to Exhibit 10.1 to…
• FY2025 10-K: …Windsor, New Jersey, which collectively are capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. The Company ceased operations at another manufacturing facility in Oakville,…
• KNSA (Kiniksa Pharmaceuticals International, plc)
• FY2025 10-K: 1 ​ ​ 107,954 ​ ​ 122,715 Cash and cash equivalents at end of period ​ $ 165,596 ​ $ 183,581 ​ $ 107,954 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Supplemental information: ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash paid for income taxes, net ​ $ 3,012 ​ $ 2,003 ​ $ 5,605 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Supplemental disclosure of non-cash investing and financing…
• FY2025 10-K: …All schedules have been omitted because they are not required or because the required information is given in the Consolidated Financial Statements or Notes thereto set forth below beginning on page F-1. (a)(3) Exhibits. See Exhibit Index. ​ 113 Table of Contents EXHIBIT INDEX ​ ​ ​ ​ Incorporated by Reference…
• HRMY (HARMONY BIOSCIENCES HOLDINGS, INC.)
• FY2025 10-K: ​ 59,469,648 Weighted average number of shares of common stock - diluted ​ 58,544,570 ​ 57,869,915 ​ 60,372,397 ​ (1) Includes $ 15,000 in related party expenses for the year ended December 31, 2025, and no related party expenses for the years ended December 31, 2024, and 2023. The accompanying notes are an integral…
• FY2025 10-K: …milestones and up to $ 240,000 upon achievement of sales-based milestones, as well as royalty rates in the mid-teens on any sales of product using the Licensed Compound in the Licensed Territories. ConSynance Agreement In August 2021, the Company entered into an asset purchase agreement with ConSynance Therapeutics,…
• SUPN (SUPERNUS PHARMACEUTICALS, INC.)
• FY2025 10-K: …revenue from Biogen's sales of ZURZUVAE to customers in the U.S., the Company utilizes certain information from Biogen, including revenue from the sale of the product and associated reserves on revenue. The following table summarizes the Company's proportionate share of the activity under the Biogen Collaboration…
• FY2025 10-K: S WorldMeds Partners, LLC and Supernus Pharmaceuticals, Inc. (incorporated by reference to Exhibit 2.1 to the Form 10-Q filed on August 17, 2020, File No. 001-35518). 2.3 #* Agreement and Plan of Merger, dated as of October 10, 2021, by and among Supernus Pharmaceuticals, Inc., Supernus Reef, Inc. and Adamas…
• CPRX (CATALYST PHARMACEUTICALS, INC.)
• FY2025 10-K: …financial statements. • Results of Operations . This section provides an analysis of our results of operations for the three fiscal years presented in the accompanying consolidated statements of operations and comprehensive income. • Liquidity and Capital Resources . This section provides an analysis of our cash…
• FY2025 10-K: …securities. See Note 15 (Stockholders' Equity). Capital Resources Based on the Company's current financial condition, including its profitability, cash flows generated from operations and forecasts of available cash, the Company believes it has sufficient funds to support operations for at least the next 12 months.…
• KRYS (Krystal Biotech, Inc.)
• FY2025 10-K: …levels of inventory in the distribution channel that will be prescribed to qualified patients and records the rebates as a reduction of revenue on the consolidated statements of operations and accrued rebates and other long-term liabilities on the consolidated balance sheets. • Commercial Rebates: The Company…
• FY2025 10-K: …(the Company) as of December 31, 2025 and 2024, the related consolidated statements of operations and comprehensive income, stockholders' equity, and cash flows for each of the years in the three-year period ended December 31, 2025, and the related notes (collectively, the consolidated financial statements). In our…
• HALO (HALOZYME THERAPEUTICS, INC.)
• FY2025 10-K: …commercial activities. We sell XYOSTED and Hylenex recombinant in the U.S. to wholesale pharmaceutical distributors, who sell Hylenex to hospitals and XYOSTED to other end-user customers. We engage Integrated Commercialization Solutions, a division of AmerisourceBergen Specialty Group, a subsidiary of…
• FY2025 10-K: …partnered products, including those under development. Our proprietary and partnered products have numerous competitors in the U.S. and abroad including, among others, major pharmaceutical and specialized biotechnology firms, universities and other research institutions that have developed competing products. Many of…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.